tGLI1 as a Therapeutic Target in Brain Metastases: A Window of Opportunity Study in Breast Cancer Brain Metastases and Primary Gliomas
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Enrollment
- 15
- Locations
- 1
- Primary Endpoint
- tGLI1 activation signature 8 (t-GAS 8)
Study Overview
Brief Summary
This trial studies the side effects and how well ketoconazole works before surgery in treating patients with glioma that has come back or breast cancer that has spread to the brain. Ketoconazole is an antifungal drug that may be able to block a protein, tGLI1 and may help to treat brain tumors.
Detailed Description
PRIMARY OBJECTIVES:
I. To determine if ketoconazole alters the tGLI1 activation signature (tGAS) which is consisted of eight validated tGLI1 regulated genes (CD24, CD44, VEGF-A, VEGF-C, VEGFR2, TEM7, OCT-4. and heparanase) in tGLI1 expressing brain biospecimens.
SECONDARY OBJECTIVES:
I. To determine if pre-treatment with ketoconazole, an inhibitor of the tGLI1 pathway in tissue culture and animal models, reduces circulating tGLI1 associated exosomal miRNA expression (miR1290 and miR1246) in brain tumor patients.
II. To describe the safety of ketoconazole when administered peri-operatively to patients with primary and secondary brain tumors.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age greater than or equal to 18 years old
- •Subjects must have a history of:
- •Histologically confirmed primary breast cancer including primary invasive and metastatic breast cancers with imaging findings consistent with brain metastasis. In the event that a patient presents with an initial diagnosis of metastatic breast cancer with imaging findings of a new brain metastases and unequivocal imaging findings of a primary breast cancer, consideration for study enrollment requires approval from the study chair (primary cohort)
- •Histologically confirmed primary glioma including astrocytoma or oligodendroglioma of any World Health Organization grade with imaging findings consistent with recurrent or progressive disease (exploratory cohort). Patients with ependymoma will not be included.
- •Subjects must be undergoing surgical resection for clinical purposes with anticipated resection of at least 300 mg of tissue.
- •Patients with any prior number of radiation (including brain radiation), chemotherapy, or surgical interventions will be eligible for this protocol.
- •The effects of ketoconazole on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- •Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document (either directly or via a legally authorized representative).
Exclusion Criteria
- •Subjects with contraindication to ketoconazole including:
- •Prior allergic reaction or intolerance of ketoconazole
- •Known active hepatitis
- •QTc prolongation (based on electrocardiography [EKG] obtained within 21 days of enrollment, with a threshold of >450 ms in males and >470 ms in female)
- •Known liver cirrhosis will be excluded from enrollment
- •Positive serum pregnancy test within 21 days of enrollment
- •Subjects currently taking medications that are included in the contraindicated concurrent medications section of the Food and Drug Administration (FDA) approved indications for ketoconazole will be required to complete a seven day wash out period prior to consideration for enrollment.
- •Subjects for whom collection of blood, or tissue samples is unsafe or clinically inadvisable.
- •Pregnant women are excluded from this study because ketoconazole is a Class B agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ketoconazole, breastfeeding should be discontinued if the mother is treated with ketoconazole.
Arms & Interventions
Arm II (standard surgery)
Patients undergo standard surgery.
Intervention: Best Practice (Other)
Arm I (ketoconazole)
Patients receive ketoconazole PO QD on days 1-4 before standard surgery in the absence of disease progression or unacceptable toxicity.
Intervention: Best Practice (Other)
Arm I (ketoconazole)
Patients receive ketoconazole PO QD on days 1-4 before standard surgery in the absence of disease progression or unacceptable toxicity.
Intervention: Ketoconazole (Drug)
Outcomes
Primary Outcomes
tGLI1 activation signature 8 (t-GAS 8)
Time Frame: Up to 30 days after surgery
The primary outcome of this study is modulation of the tGLI1 pathway as assessed by the tGLI1 activation signature 8 (t-GAS 8) \[29, 40\]. t-GAS 8 consists of eight validated tGLI1 regulated genes (CD24, CD44, VEGF-A, VEGF-C, VEGFR2, TEM7, OCT-4. and heparanase) and is measured using qPCR in patients whose brain tissue expresses tGLI1 (by IHC). The distribution of the tGAS will be examined and transformed to approximate the conditional normality assumption if necessary. Analysis of variance (ANOVA) methods will be used to determine the effects of different factors of interest (e.g., treatment or tumor type) on the outcomes measured.
Secondary Outcomes
- Blood brain penetrance of ketoconazole in serum relative to enhancing brain tissue(Up to 30 days after surgery)
- tGLI1 pathway activation(Up to 30 days after surgery)
- Incidence of adverse events (AEs)(Up to 30 days after surgery)